WT 4869

Drug Profile

WT 4869

Alternative Names: WT4869

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Chugai Pharmaceutical; Dainippon Sumitomo Pharma
  • Developer Chugai Pharmaceutical; Sumitomo Dainippon Pharma
  • Class Cancer vaccines; Peptide vaccines; Peptides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Myelodysplastic syndromes
  • Phase I Solid tumours
  • Discontinued Non-small cell lung cancer

Most Recent Events

  • 31 Dec 2016 Sumitomo Dainippon Pharma completes a phase I/II extension trial in Myelodysplastic syndromes in Japan (JapicCTI142672)
  • 03 Dec 2016 Efficacy data from a phase I/II trial in Myelodysplastic syndrome released by Sumitomo Dainippon Pharma
  • 31 Jul 2015 Sumitomo Dainippon Pharma terminates a phase I/II trial in Non-small cell lung cancer in Japan (UMIN000010027)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top